Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185her2/neu and the EGFR–p185her2/neu complexes (original) (raw)

• Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI et al. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127–137.
  Article CAS PubMed Google Scholar
• Berezov A, Chen J, Liu Q, Zhang HT, Greene MI, Murali R . (2002). Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem 277: 28330–28339.
  Article CAS PubMed Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289.
  Article CAS PubMed PubMed Central Google Scholar
• Cho HS, Leahy DJ . (2002). Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297: 1330–1333.
  Article CAS PubMed Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756–760.
  Article CAS PubMed Google Scholar
• Cohen JA, Weiner DB, More KF, Kokai Y, Williams WV, Maguire Jr HC et al. (1989). Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4: 81–88.
  CAS PubMed Google Scholar
• Drebin JA, Link VC, Greene MI . (1988). Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2: 273–277.
  CAS PubMed Google Scholar
• Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI . (1985). Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 697–706.
  Article CAS PubMed Google Scholar
• Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI . (1984). Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 312: 545–548.
  Article CAS PubMed Google Scholar
• Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA . (2003). EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507–517.
  Article CAS PubMed Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, De Vos AM, Sliwkowski MX . (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.[see comment]. Cancer Cell 5: 317–328.
  Article CAS PubMed Google Scholar
• Guex N, Peitsch MC . (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714–2723.
  Article CAS PubMed Google Scholar
• Jackson JG, St Clair P, Sliwkowski MX, Brattain MG . (2004). Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601–2609.
  Article CAS PubMed Google Scholar
• Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P et al. (1995). Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1: 644–648.
  Article CAS PubMed Google Scholar
• Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L et al. (1990). p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184–5187.
  CAS PubMed Google Scholar
• Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG et al. (1989). Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58: 287–292.
  Article CAS PubMed Google Scholar
• Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670.
  Article CAS PubMed PubMed Central Google Scholar
• Lodato RF, Maguire Jr HC, Greene MI, Weiner DB, LiVolsi VA . (1990). Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 3: 449–454.
  CAS PubMed Google Scholar
• Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D . (2002). Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62: 5485–5488.
  CAS PubMed Google Scholar
• Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH et al. (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775–787.
  Article CAS PubMed Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684.
  Article CAS PubMed Google Scholar
• Sanner MF . (1999). Python: a programming language for software integration and development. J Mol Graph Model 17: 57–61.
  CAS PubMed Google Scholar
• Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437–441.
  Article CAS PubMed PubMed Central Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.
  Article CAS PubMed Google Scholar
• Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S et al. (2005). 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104: 2701–2708.
  Article CAS PubMed Google Scholar
• van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R . (1987). Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7: 2019–2023.
  Article CAS PubMed PubMed Central Google Scholar
• Wada T, Myers JN, Kokai Y, Brown VI, Hamuro J, LeVea CM et al. (1990a). Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene 5: 489–495.
  CAS PubMed Google Scholar
• Wada T, Qian XL, Greene MI . (1990b). Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61: 1339–1347.
  Article CAS PubMed Google Scholar
• Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI . (1989). A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339: 230–231.
  Article CAS PubMed Google Scholar
• Williams TM, Weiner DB, Greene MI, Maguire Jr HC . (1991). Expression of c-erbB-2 in human pancreatic adenocarcinomas. Pathobiology 59: 46–52.
  Article CAS PubMed Google Scholar